Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $240 from $227 and keeps a Buy rating on the shares after the company reported “solid” Q4 results and provided initial 2026 guidance that was slightly ahead of sell-side estimates. Following the quarter, the firm is making several adjustments to its model, including raising near-term Tremfya estimates, accelerating Stelara erosion, and raising estimates for multiple newer products, says the analyst, who continues to identify J&J as a Top Picks in the large cap biopharma sector.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $265 from $230 at Scotiabank
- Johnson & Johnson price target raised to $250 from $222 at TD Cowen
- Johnson & Johnson Stock Trending Among Wall Street Analysts
- Johnson & Johnson price target raised to $200 from $197 at Morgan Stanley
- Johnson & Johnson price target raised to $220 from $205 at Stifel